ArticleNature immunology2017
Regulation of autoantibody activity by the IL-23-T
Open access · bronzeAbstract read
In one paragraph
Article in Nature immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 177 papers.
0numbers the graph read from it
0cells of the map it votes in
177citing papers in PubMed
18.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
177 citing papers in PubMed, 310 citations in OpenAlex.
- Glycomic Signatures of Plasma IgG Improve Preoperative Prediction of the Invasiveness of Small Lung Nodules.Molecules (Basel, Switzerland) · 2019Trial
- High-throughput characterization of the functional impact of IgG Fc glycan aberrancy in juvenile idiopathic arthritis.Glycobiology · 2017Trial
- Glycoproteomic Signatures of IgG SubclassMedComm · 2026Article
- Interleukin-10 enhances IgG galactosylation and sialylation.Biomarker research · 2026Article
- The evolving landscape of complement therapeutics in rheumatology.Annals of the rheumatic diseases · 2026Review
- Enhancing IgG fragment crystallizable sialylation improves the therapeutic activity of IL-23 cytokine blockade.JCI insight · 2026Article
- Risankizumab redefines Crohn's treatment after ustekinumab failure.World journal of gastrointestinal pharmacology and therapeutics · 2026Article
- The Role and Safety of Aluminum Adjuvants in Childhood Vaccines.Pediatrics · 2026Review
- Differences in IgG Sialylation Distinguish Asymptomatic From Symptomatic Antinuclear Antibody-Positive Individuals.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- microRNAs as Biomarkers and Therapeutic Targets in Rheumatoid Arthritis.International journal of molecular sciences · 2025Review
- Multivariate analysis of glycogenes reveals coordinated regulation of immunoglobulin glycosylation in an immortalized human B cell system.bioRxiv : the preprint server for biology · 2025Article
- Unraveling the mechanisms of bone diseases: targeting dendritic cells in osteoimmunology for internal homeostasis balance.Bone research · 2025Review
- Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity.Cancer cell · 2025Article
- Deep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis.The Journal of clinical investigation · 2025Article
- State-of-the-Art Review on the Treatment of Axial Spondyloarthritis.Medical sciences (Basel, Switzerland) · 2025Review
- Pathogenic and Nonpathogenic Antibody Responses in Allergic Diseases.European journal of immunology · 2025Review
- Profiling of IgG N-glycosylation for axial spondyloarthritis and other rheumatic diseases.Arthritis research & therapy · 2025Article
- Microbial pathways contributing to the pathogenesis of rheumatoid arthritis.Seminars in arthritis and rheumatism · 2025Review
- Role of Antibody Glycosylation in Health, Disease, and Therapy.Handbook of experimental pharmacology · 2025Review
- Circulating miRNAs as potential non-invasive biomarkers for ANCA-associated glomerulonephritis.Frontiers in immunology · 2025Article
117 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
34 authors at 6 institutions in 5 countries.
René PfeifleDepartment of Internal Medicine 3 and Institute for Clinical Immunology, University Hospital Erlangen, Erlangen, Germany.
Tobias RotheDepartment of Internal Medicine 3 and Institute for Clinical Immunology, University Hospital Erlangen, Erlangen, Germany.
Natacha IpseizDepartment of Internal Medicine 3 and Institute for Clinical Immunology, University Hospital Erlangen, Erlangen, Germany.
Hans U SchererDepartment of Rheumatology, Leiden University Medical Centre, Leiden, the Netherlands.
Stephan CulemannDepartment of Internal Medicine 3 and Institute for Clinical Immunology, University Hospital Erlangen, Erlangen, Germany.
Ulrike HarreDepartment of Internal Medicine 3 and Institute for Clinical Immunology, University Hospital Erlangen, Erlangen, Germany.
Jochen A AckermannDepartment of Internal Medicine 3 and Institute for Clinical Immunology, University Hospital Erlangen, Erlangen, Germany.
Martina SeefriedNikolaus-Fiebiger Center for Molecular Medicine, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Arnd KleyerDepartment of Internal Medicine 3 and Institute for Clinical Immunology, University Hospital Erlangen, Erlangen, Germany.
Stefan UderhardtDepartment of Internal Medicine 3 and Institute for Clinical Immunology, University Hospital Erlangen, Erlangen, Germany.
Benjamin HauggDepartment of Internal Medicine 3 and Institute for Clinical Immunology, University Hospital Erlangen, Erlangen, Germany.
Axel J HueberDepartment of Internal Medicine 3 and Institute for Clinical Immunology, University Hospital Erlangen, Erlangen, Germany.
Patrick DaumNikolaus-Fiebiger Center for Molecular Medicine, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0002-7577-070X
Gordon F HeidkampDepartment of Dermatology, Laboratory of Dendritic Cell Biology, University Hospital Erlangen, Erlangen, Germany.
Changrong GeMedical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Sybille BöhmInstitute of Genetics at the Department of Biology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Anja LuxInstitute of Genetics at the Department of Biology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Wolfgang SchuhNikolaus-Fiebiger Center for Molecular Medicine, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Iryna MagorivskaDepartment of Internal Medicine 3 and Institute for Clinical Immunology, University Hospital Erlangen, Erlangen, Germany.
Kutty S NandakumarMedical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-7790-8197
Erik LönnblomMedical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Christoph BeckerDepartment of Medicine 1, University Hospital Erlangen, Erlangen, Germany.
Diana DudziakDepartment of Dermatology, Laboratory of Dendritic Cell Biology, University Hospital Erlangen, Erlangen, Germany.
Manfred WuhrerCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands.
Yoann RomboutsDepartment of Rheumatology, Leiden University Medical Centre, Leiden, the Netherlands.ORCID 0000-0003-4482-2199
Carolien A KoelemanCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands.
René ToesDepartment of Rheumatology, Leiden University Medical Centre, Leiden, the Netherlands.
Thomas H WinklerNikolaus-Fiebiger Center for Molecular Medicine, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Rikard HolmdahlMedical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-4969-2576
Martin HerrmannDepartment of Internal Medicine 3 and Institute for Clinical Immunology, University Hospital Erlangen, Erlangen, Germany.ORCID 0000-0002-0258-2484
Stephan BlümlDivision of Rheumatology, Internal Medicine 3, Medical University Vienna, Vienna, Austria.ORCID 0000-0002-2758-4400
Falk NimmerjahnInstitute of Genetics at the Department of Biology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Georg SchettDepartment of Internal Medicine 3 and Institute for Clinical Immunology, University Hospital Erlangen, Erlangen, Germany.
Gerhard KrönkeDepartment of Internal Medicine 3 and Institute for Clinical Immunology, University Hospital Erlangen, Erlangen, Germany.
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEUniversitätsklinikum Erlangen · DEKarolinska Institutet · SELeiden University Medical Center · NLCentre National de la Recherche Scientifique · FRMedical University of Vienna · AT
Funding
European Research Council 640087
Abstract
The checkpoints and mechanisms that contribute to autoantibody-driven disease are as yet incompletely understood. Here we identified the axis of interleukin 23 (IL-23) and the T
Indexed as
Immune ToleranceAnimalsArthritis, RheumatoidAutoantibodiesbeta-D-Galactoside alpha 2-6-SialyltransferaseB-LymphocytesCell DifferentiationCells, CulturedDisease Models, AnimalGlycosylationHumansImmunoglobulin GInterleukin-21Interleukin-22Interleukin-23InterleukinsAutoantibodiesbeta-D-Galactoside alpha 2-6-SialyltransferaseImmunoglobulin GInterleukin-21Interleukin-22Interleukin-23InterleukinsSialyltransferases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.